A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany…
Browsing: oncology
February 26, 2025 | By Michael Karin, Phd Liver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
MRI’s Role in Prostate Cancer Diagnosis – A 3-Year Study Breakthrough Date: February 20, 2025 Prostate cancer, the second most…
FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On…
On February 14, 2025, the U.S. Food and Drug Administration (FDA) delivered a Valentine’s Day gift to patients battling symptomatic…
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At…
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD,…
Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer…
Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed…
FDA Approves Mirdametinib for NF1-PN: A New Option for Patients Introduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks…
Introduction: Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025, as detailed in their educational…
Date: February 8, 2025 The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a…
Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients…
Abstract: Circulating tumor DNA (ctDNA) has a short half-life (<2 hours) which may permit real-time monitoring of tumor status. This…
In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP) via liquid biopsy has become…
In the evolving landscape of cancer care In the evolving landscape of cancer care, the use of circulating tumor DNA…
In a recent interview with Dr. Ignacio Garrido-Laguna from the University of Utah Health, we gained fascinating insights into the…
On January 16, 2025, a significant advancement in cancer treatment was announced. The FDA approved a new therapeutic option for…
In an enlightening discussion at the latest medical symposium, Dr. Jonathan Nowak, MD from Brigham and Women’s Hospital, shared critical…
The latest findings from the BREAKWATER study, a phase 3 clinical trial, have shown significant strides in improving treatment outcomes…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer…
In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.
The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.
The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU®…
Overview of the CONFORM™ Platform The CONFORM™ platform by EDETEK offers a multifaceted approach to managing clinical data, focusing on…
The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered…
Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or…
On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…
Introduction ASCO 2024 Head & Neck Cancer developments brought forth several groundbreaking studies in the field of head and neck…
Genetic Testing Cancer In recent years, the field of oncology has witnessed significant advancements, particularly in the realm of genetic…
Author: Dr. Regina Barragan-Carillo, City of Hope Overview: At ASCO 2024, Dr. Regina Barragan-Carillo from City of Hope Cancer Center…
Presented by Dr. Hedyeh Ebrahimi, City of Hope Overview: At the ASCO 2024 conference, Dr. Hedyeh Ebrahimi of City of…
Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of…
Introduction At a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor…
Introduction During the CAR-T & Bispecifics Conference, Dr. Brian Sworder, MD, from UCI Irvine, shared compelling insights on the utility…
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series…
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel…
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test…
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary…
This immersive practice guide offers “how to†methods and day-to-day strategies via faculty commentary and a review of data and…
Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? Through this…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…